Compass Pathways wins FDA IND acceptance for COMP360 PTSD trial

Merck completes acquisition of Cidara Therapeutics for USD9.2bn

HUTCHMED reports positive Phase III results for sovleplenib in wAIHA

GSK reports positive phase III results for bepirovirsen in chronic hepatitis B

Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial

Legacy Healthcare's Cinainu gains US FDA approval to advance multi-regional Phase 3 trial in alopecia areata

Health Canada approves AbbVie's eight-week MAVIRET regimen for acute and chronic hepatitis C

Cartography Biosciences partners with Pfizer to discover tumour-selective antigens

Nimbus Therapeutics partners with Lilly to develop oral obesity treatment

BioArctic and Eisai secure Chinese acceptance for subcutaneous Leqembi filing

Oculis secures FDA Breakthrough Therapy Designation for Privosegtor in optic neuritis

Nanjing Delova Biotech reports positive Phase 3 trial results for QP-6211 for postoperative pain

MetaVia reports positive results from Phase 1 clinical trial in obesity

RedHill advances RHB-102 across GI indications

Halozyme licenses ENHANZE to Skye Bioscience for nimacimab obesity programme